The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist?
Abstract
Adverse drug reactions, due at least in part to interindividual variability in drug response, rank between the 4th and 6th leading causes of death in the USA. The field of ‘pharmacogenetics’, which is ‘the study of variability in drug response due to heredity’, should help in reducing drug‐caused morbidity and mortality. The recently coined term ‘pharmacogenomics’ usually refers to ‘the field of new drug development based on our rapidly increasing knowledge of all genes in the human genome’. However, the two terms – pharmacogenetics and pharmacogenomics – are often used interchangeably. A classification of more than five dozen pharmacogenetic differences is presented here. Most of these variations occur in drug‐metabolizing enzyme (DME) genes, with some presumed to exist in the DME receptor and drug transporter genes, and others have not yet been explained on a molecular basis. A method for unequivocally defining a quantitative phenotype (drug efficacy, toxicity, etc.) is proposed; this is where help from the clinical geneticist can be especially important. Our current appreciation of the degree of variability (including single‐nucleotide polymorphisms, SNPs) in the human genome is described, with emphasis on the need to prove that a particular genotype is indeed the cause of a specific phenotype; this topic has been termed ‘functional genomics’. Furthermore, the current amount of admixture amongst almost all ethnic groups will obviously make studies of gene–drug interactions more complicated, as will the withholding of ethnic information about DNA samples during any molecular epidemiologic study. DME genes and DME receptor and drug transporter genes can be regarded as ‘modifier genes’, because they influence disorders as diverse as risk of cancer, bone marrow toxicity resulting from occupational exposure, and Parkinson's disease; for this reason, the clinical geneticist, as well as the medical genetics counselor, should be knowledgeable in the rapidly expanding fields of pharmacogenetics and pharmacogenomics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Future of Genetic Studies of Complex Human Diseases
Risch, N., & Merikangas, K. (1996) · Science · doi:10.1126/science.273.5281.1516 · Cited by 5,355
Incidence of Adverse Drug Reactions in Hospitalized Patients: A Meta-analysis of Prospective Studies
Lazarou, J., Pomeranz, B. H., & Corey, P. N. (1998) · JAMA · doi:10.1001/jama.279.15.1200 · Cited by 4,807
Genetic Dissection of Complex Traits
Lander, E. S., & Schork, N. J. (1994) · Science · doi:10.1126/science.8091226 · Cited by 3,413
King, M.-C., & Wilson, A. C. (1975) · Science · doi:10.1126/science.1090005 · Cited by 2,815
Wang, D. G., Fan, J.-B., Siao, C.-J., Berno, A., Young, P., Sapolsky, R., Ghandour, G., Perkins, N., Winchester, E., Spencer, J., et al. (1998) · Science · doi:10.1126/science.280.5366.1077 · Cited by 2,161
Characterization of single-nucleotide polymorphisms in coding regions of human genes
Cargill, M., Altshuler, D., Ireland, J., Sklar, P., Ardlie, K., Patil, N., Lane, C. R., Lim, E. P., Kalyanaraman, N., Nemesh, J., et al. (1999) · Nature Genetics · doi:10.1038/10290 · Cited by 1,547
The New Genomics: Global Views of Biology
Lander, E. S. (1996) · Science · doi:10.1126/science.274.5287.536 · Cited by 1,174
Variations on a Theme: Cataloging Human DNA Sequence Variation
Collins, F. S., Guyer, M. S., & Chakravarti, A. (1997) · Science · doi:10.1126/science.278.5343.1580 · Cited by 1,050
Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis
Halushka, M. K., Fan, J.-B., Bentley, K., Hsie, L., Shen, N., Weder, A., Cooper, R., Lipshutz, R., & Chakravarti, A. (1999) · Nature Genetics · doi:10.1038/10297 · Cited by 1,012
Genetic mapping of a gene causing hypertension in the stroke-prone spontaneously hypertensive rat
Jacob, H. J., Lindpaintner, K., Lincoln, S. E., Kusumi, K., Bunker, R. K., Mao, Y.-P., Ganten, D., Dzau, V. J., & Lander, E. S. (1991) · Cell · doi:10.1016/0092-8674(91)90584-l · Cited by 719
Cited by
Biological Activity of Ionic Liquids and Their Application in Pharmaceutics and Medicine
Egorova, K. S., Gordeev, E. G., & Ananikov, V. P. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00562 · Cited by 1,649
Clinical importance of the cytochromes P450
Nebert, D. W., & Russell, D. W. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11203-7 · Cited by 1,414
Self-citationLonjou, C., Borot, N., Sekula, P., Ledger, N., Thomas, L., Halevy, S., Naldi, L., Bouwes-Bavinck, J.-N., Sidoroff, A., de Toma, C., et al. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3282f3ef9c · Cited by 624
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
Trends in biomarker research for cancer detection
Srinivas, P. R., Kramer, B. S., & Srivastava, S. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(01)00560-5 · Cited by 411
Metadata
- Authors
- Nebert, D. W.
- Venue
- Clinical Genetics
- Publisher
- Wiley
- Published
- 1999-10
- Volume
- 56
- Issue
- 4
- Pages
- 247-258
- ISSN
- 0009-9163 (ISSN-L)
- 1399-0004
- OpenAlex
- W2024875479
- Cited by
- 272
- References
- 42
- FWCI
- 18.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? https://app.cochat.ai/papers/10.1034/j.1399-0004.1999.560401.x
- The paper
- Nebert, D. W. (1999). Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clinical Genetics. https://doi.org/10.1034/j.1399-0004.1999.560401.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.